Patent Application
20130096068
The present invention generally relates to pharmaceutical compositions and methods for treating cancer, and particularly to a combination therapy of cancer using a proteasome inhibitor and a gallium complex.
Bortezomib developed by Millennium Pharmaceuticals (now part of Eisai Pharmaceuticals) as a proteasome inhibitor has been marketed for treating multiple myeloma. In addition, bortezomib has been shown to be useful in preclinical models and is being tested in clinical trials for various other types of cancer. Other proteasome inhibitors are disclosed in U.S. Pat. Nos. 5,780,454 and 7,442,830; PCT Publication Nos. WO 07/0005991, WO 02/096933, WO 05/016859, WO 05/021558 and WO 06/08660.
Tris(8-quinolinolato)gallium(III) is an organic gallium complex that has been suggested to be useful in certain types of cancer. For example, U.S. Pat. No. 7,919,486 discloses and claims the use of tris(8-quinolinolato)gallium(III) and related compounds for the treatment of melanoma.
It has been surprisingly discovered that the combined use of a compound of Formula (I) below, particularly tris(8-quinolinolato)gallium(III), and a proteasome inhibitor such as bortezomib can create unexpected synergies in killing tumor cells and therefore treating cancers. Accordingly, in a first aspect, the present invention provides a method of treating cancer in a patient in need of such treatment comprising administering, simultaneously or sequentially, to the patient a therapeutically effective amount of a compound of Formula (I) and a proteasome inhibitor such as bortezomib.
In accordance with a second aspect, a pharmaceutical composition is provided comprising a therapeutically effective amount of a compound of Formula (I) below, particularly tris(8-quinolinolato)gallium(III), and a proteasome inhibitor such as bortezomib.
In accordance with another aspect of the present invention, a kit is provided comprising in a compartmentalized container a first unit dosage form having a compound of Formula (I) below, e.g., tris(8-quinolinolato)gallium(III), and a second unit dosage form having a proteasome inhibitor such as bortezomib. Optionally, instructions on how to use the kit are included in the kit.
The foregoing and other advantages and features of the invention, and the manner in which the same are accomplished, will become more readily apparent upon consideration of the following detailed description of the invention taken in conjunction with the accompanying examples, which illustrate preferred and exemplary embodiments.
The present invention provides a method of treating cancer by a combination therapy. The method comprises treating a cancer patient in need of treatment with a therapeutically effective amount of (1) a compound of Formula (I)
wherein R1 represents hydrogen, a halogen or a sulfono group SO3M, in which M is a metal ion, and R2 represents hydrogen, or R1 is Cl and R2 is I, or a pharmaceutically acceptable salt thereof, and (2) a proteasome inhibitor.
As used herein, the phrase “treating . . . with . . . ” means administering a compound to the patient or causing the formation of a compound inside the patient. As used herein, the term “pharmaceutically acceptable salts” refers to the relatively non-toxic, organic or inorganic salts of the active compounds, including inorganic or organic acid addition salts of the compound.
In one embodiment, the method of treating cancer comprises (1) administering to a cancer patient in need of treatment a therapeutically effective amount of a compound of Formula (I):
wherein R1 represents hydrogen, a halogen or a sulfono group SO3M, in which M is a metal ion, and R2 represents hydrogen, or R1 is Cl and R2 is I, or a pharmaceutically acceptable salt thereof; and (2) administering to said cancer patient a therapeutically effective amount of a proteasome inhibitor. To put it differently, in accordance with this embodiment, the method comprises administering a therapeutically effective amount of a compound of Formula (I) above or a pharmaceutically acceptable salt thereof to a cancer patient who is under treatment of a proteasome inhibitor, or administering a therapeutically effective amount of a proteasome inhibitor to a cancer patient who is under treatment of a compound of Formula (I) above or a pharmaceutically acceptable salt thereof.
In another embodiment, the present invention provides a use of a compound of Formula (I) above or a pharmaceutically acceptable salt thereof for the manufacture of a medicament useful in combination with a proteasome inhibitor such as bortezomib for treating cancer. In yet another embodiment, the present invention provides a use of a proteasome inhibitor such as bortezomib for the manufacture of a medicament useful in combination with a compound of Formula (I) above or a pharmaceutically acceptable salt thereof for treating cancer.
In preferred embodiments, the compound is tris(8-quinolinolato)gallium(III)
or a pharmaceutically acceptable salt thereof.
Proteasome inhibitors are inhibitors of the 26S proteasome in mammalian cells. The 26S proteasome is a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome prevents this targeted proteolysis, which can affect multiple signaling cascades within the cell including the NF-κB pathway. This disruption of normal homeostatic mechanisms can lead to cell death. Many proteasome inhibitors specifically inhibit the chymotrypsin-like activity of the 26S proteasome in mammalian cells. Any known proteasome inhibitors known in the art are useful in the present invention, including, but not limited to, those disclosed in U.S. Pat. Nos. 5,780,454 and 7,442,830; WO 07/0005991, WO 02/096933, WO 05/016859, WO 05/021558 and WO 06/08660, the relevant part of each of which is incorporated herein by reference.
Preferred proteasome inhibitors for the present invention may be selected from the group consisting of peptidyl aldehydes, boronic acids, boronic esters, lactacystin, and lactacystin analogs. In preferred embodiments, the proteasome inhibitor may be lactacystin or a lactacystin analog, particularly lactacystin, clasto-lactacystin β-lactone, 7-ethyl-clasto-lactacystin β-lactone, 7-n-propyl-clasto-lactacystin β-lactone, or 7-n-butyl-clasto-lactacystin β-lactone.
In some embodiments, the proteasome inhibitor is selected from the group of [(1R)-1-({[(2,3-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(5-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(3,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(2,5-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(2-bromobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(2-chloro-5-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(4-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(3,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(3-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(2,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(3,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(3-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(2-chloro-4-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(2,3-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(2-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(2,4-difluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(4-chloro-2-fluorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(4-chlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, [(1R)-1-({[(2,4-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, and [(1R)-1-({[(3,5-dichlorobenzoyl)amino]acetyl}amino)-3-methylbutyl]boronic acid, and esters (e.g., mannitol esters), salts thereof and boronic acid anhydride thereof.
In preferred embodiments, the proteasome inhibitor is bortezomib, CEP-18770 (See Piva et al., Blood, 111(5):2765-75 (2008)), carfilzomib or MLN9708.
In some preferred embodiments, the combination method of the present invention is used in treating hematological neoplasms such as multiple myeloma, lymphoma (e.g., multiple lymphoma, mantle cell lymphoma, Hodgkin lymphoma, non-Hodgkin's lymphoma, diffuse large cell lymphoma, lymphoplasmacytic lymphoma, Mature T cell and natural killer (NK) cell neoplasms), and leukemia (e.g., acute myelogenous leukemia, myelodysplasia, and myelodysplastic syndromes). In other embodiments, the combination method is used in treating amyloidosis, chronic graft versus host disease, and in preventing rejection in transplantation.
In a specific embodiment, multiple myeloma is treated by simultaneously or sequentially administering a pharmaceutically effective amount of (1) tris(8-quinolinolato)gallium(III) and (2) a proteasome inhibitor (e.g., bortezomib, CEP-18770, carfilzomib or MLN9708, preferably bortezomib).
In other embodiments, the combination method of the present invention is used in treating solid tumors particularly lung cancer, colon cancer, breast cancer, ovarian cancer, prostate cancer, liver cancer, mesothelioma, urethral or bladder cancer, renal cancer, neuroblastoma, glioblastoma, gliosarcoma, and melanoma.
In certain embodiments, the combination therapy method is used to treat cancer patients having tumors that exhibit resistance to bortezomib or another proteasome inhibitor. In other words, the method of the present invention is used to treat a cancer patient having previously been treated with a proteasome inhibitor such as bortezomib, and whose cancer was found to be non-responsive to the proteasome inhibitor or have developed resistance to the proteasome inhibitor treatment. In other embodiments, the method of present invention is used to treat a cancer patient refractory to a treatment with a proteasome inhibitor such as bortezomib, that is, who has previously been treated with a proteasome inhibitor such as bortezomib, and whose cancer was initially responsive to the previously administered proteasome inhibitor such as bortezomib, but was subsequently found to have relapsed.
Patients undergoing initial treatment with a proteasome inhibitor such as bortezomib can be carefully monitored for signs of resistance, non-responsiveness or refractory cancer. This can be accomplished by monitoring the patient's cancer's response to the proteasome inhibitor such as bortezomib treatment. The response, lack of response, or relapse of the cancer to initial treatment with a proteasome inhibitor such as bortezomib can be determined by any suitable method practiced in the art. For example, in the case of solid tumor cancers this can be accomplished by the assessment of tumor size and number. An increase in tumor size or, alternatively, tumor number, indicates that the tumor is not responding to the chemotherapy, or that a relapse has occurred. The determination can be done according to the “RECIST” criteria as described in detail in Therasse et al, J. Natl. Cancer Inst. 92:205-216 (2000).
Thus, in these various embodiments, in accordance with the present invention, a patient having cancer (e.g., the specific types of cancer described above) is identified or diagnosed, and such patient is treated with a therapeutically effective amount of a proteasome inhibitor such as bortezomib as well as a therapeutically effective amount of a compound of Formula (I) such as tris(8-quinolinolato)gallium(III).
In the combination therapy method of the present invention, the compound of Formula (I) such as tris(8-quinolinolato)gallium(III) and the proteasome inhibitor can be administered at about the same time, or separately according to their respective dosing schedules. When administered at about the same time, the gallium compound and the proteasome inhibitor can be administered in the same pharmaceutical composition or in separate dosage unit forms. For example, in one embodiment of the combination method of the present invention, the compound tris(8-quinolinolato)gallium(III) can be administered, e.g., orally at a dosing of from 0.1 mg to 3000 mg at, e.g., four times a day, while the proteasome inhibitor bortezomib may be administered intravenously (e.g., bolus IV injection) once or twice weekly each at an amount of from 0.7 mg/m2 to about 1.3 mg/m2.
It should be understood that the dosage ranges set forth above are exemplary only and are not intended to limit the scope of this invention. The therapeutically effective amount for each active compound can vary with factors including but not limited to the activity of the compound used, stability of the active compound in the patient's body, the severity of the conditions to be alleviated, the total weight of the patient treated, the route of administration, the ease of absorption, distribution, and excretion of the active compound by the body, the age and sensitivity of the patient to be treated, adverse events, and the like, as will be apparent to a skilled artisan. The amount of administration can be adjusted as the various factors change over time.
The pharmaceutical compounds in the method of present invention can be administered in any suitable unit dosage forms. Suitable oral formulations can be in the form of tablets, capsules, suspension, syrup, chewing gum, wafer, elixir, and the like. Pharmaceutically acceptable carriers such as binders, excipients, lubricants, and sweetening or flavoring agents can be included in the oral pharmaceutical compositions. If desired, conventional agents for modifying tastes, colors, and shapes of the special forms can also be included. In addition, for convenient administration by enteral feeding tube in patients unable to swallow, the active compounds can be dissolved in an acceptable lipophilic vegetable oil vehicle such as olive oil, corn oil and safflower oil.
For injectable formulations, the pharmaceutical compositions can be in lyophilized powder in admixture with suitable excipients in a suitable vial or tube. Before use in the clinic, the drugs may be reconstituted by dissolving the lyophilized powder in a suitable solvent system to form a composition suitable for intravenous or intramuscular injection.
In accordance with another aspect of the present invention, a pharmaceutical composition is provided, comprising a therapeutically effective amount of a compound of Formula (I) such as tris(8-quinolinolato)gallium(III) as well as a therapeutically effective amount of a proteasome inhibitor.
In accordance with another aspect of the present invention, a pharmaceutical kit is provided comprising, in a compartmentalized container, (1) a unit dosage form of a compound of Formula (1) such as tris(8-quinolinolato)gallium(III); and (2) a unit dosage form of a proteasome inhibitor. As will be apparent to a skilled artisan, the amount of a therapeutic compound in the unit dosage form is determined by the dosage to be used on a patient in the method of the present invention. In one embodiment of the kit, tris(8-quinolinolato)gallium(III) is in a tablet or capsule or any other suitable form at an amount of, e.g., 0.1 mg to about 3000 mg per unit dosage form. The kit further includes a proteasome inhibitor in a unit dosage of from about 0.1 mg to about 2000 mg in a tablet or capsule form or in lyophilized powder. In a specific embodiment, the proteasome inhibitor is bortezomib, and the kit includes a vial containing from about 0.5 mg to about 10 mg, preferably about 3.5 mg of bortezomib as a sterile lyophilized powder. Optionally, the kit further comprises instructions for using the kit in the combination therapy method in accordance with the present invention.
To determine whether the combination of tris(8-quinolinolato)gallium(III) and bortezomib produces synergistic effect using the constant ratio combination design of Chou and Talalay, the combination was tested in cell lines including multiple myeloma cell lines ARH-77, RPMI 8226, OPM-2, NCI-H929 with Promega's Cell Titer-Glo® assay. Specifically, the human tumor cells were placed in a 96-well microculture plate at the appropriate density for 96 hours of total growth time. After 24 hours of incubation in a humidified incubator at 37° C. with 5% CO2 and 95% air, serially diluted test agents in growth medium were added to each well. After 96 total hours of culture in a CO2 incubator, the plates were processed with Cell Titer-Glo (Promega #G7571) according to manufacturer's instructions. Luminescence was detected using a Tecan GENios microplate reader. Percent inhibition of cell growth was calculated relative to untreated control wells. All tests were performed in duplicate at each concentration level.
The cells (in quadruplicate wells) were incubated with tris(8-quinolinolato)gallium(III) alone, bortezomib alone, or mixture of tris(8-quinolinolato)gallium(III) and bortezomib. Drug ratios were equivalent to the ratio of respective IC50 of agents being combined. Assuming a combination response of near additivity, drug concentrations bracketed the sum of one half of the respective IC50's with serial dilutions selected based upon the inhibition curves of the agents being combined, (typically 1.5 fold dilutions) with a total of seven drug concentrations.
Combination of tris(8-quinolinolato)gallium(III) and bortezomib showed synergism. For example,
MTT cytotoxicity assays were performed with combination of tris(8-quinolinolato)gallium(III) and bortezomib in lung cancer cell lines A549 and A427, and colon cancer cell line SW480.
Cells were plated (2×103 cells in 100 μl/well) in 96-well plates and allowed to recover for 24 hours before drugs were added in another 100 μl growth medium and cells exposed for the indicated time periods. For pulsing experiments, test medium was replaced with fresh (drug-free) culture medium after the indicated exposure times. After 72 hours of drug treatment, the proportion of viable cells was determined after by MTT assay following the manufacturer's recommendations (EZ4U, Biomedica, Vienna, Austria). Combination of tris(8-quinolinolato)gallium(III) and bortezomib showed synergism in cells. For example,
All publications and patent applications mentioned in the specification are indicative of the level of those skilled in the art to which this invention pertains. All publications and patent applications are herein incorporated by reference to the same extent as if each individual publication or patent application was specifically and individually indicated to be incorporated by reference. The mere mentioning of the publications and patent applications does not necessarily constitute an admission that they are prior art to the instant application.
Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims.
This application is a continuation of PCT/US11/32937 filed Apr. 19, 2011, which is entitled to the priority of U.S. Provisional Application No. 61/325,571 filed on Apr. 19, 2010, which is incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| 61325571 | Apr 2010 | US |
| Number | Date | Country | |
|---|---|---|---|
| Parent | PCT/US2011/032937 | Apr 2011 | US |
| Child | 13655475 | US |
